<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28510" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rhabdomyosarcoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaseb</surname>
            <given-names>Hatem</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kuhn</surname>
            <given-names>James</given-names>
          </name>
          <aff>Aventura Hospital and Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gasalberti</surname>
            <given-names>David P.</given-names>
          </name>
          <aff>Inspira Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hatem Kaseb declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Kuhn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Gasalberti declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28510.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma that is believed to originate from primitive mesenchymal cells that typically differentiate into skeletal tissue. However, these tumors can also arise in other types of tissue and any anatomic area. RMS is the most common soft tissue sarcoma diagnosed in children; only 1% to 2% of these cancers are found in adults. The etiology and risk factors remain largely unknown. Most cases of rhabdomyosarcoma are sporadic; however, the disease can be associated with familial syndromes.&#x000a0;Rhabdomyosarcoma is classified into histologic subtypes: embryonal, alveolar, pleomorphic, spindle, and mixed-type. Embryonal is the most commonly occurring subtype and also has the best prognosis.&#x000a0;The management approach is tailored to a patient's risk stratification. Two systems are used to characterize risk stratification for RMS: the Clinical Group or the Stage. Each system uses different factors to categorize patients according to risk, and most authorities use both to determine the most appropriate therapeutic approach.&#x000a0;Currently, treatment is multimodal, combining surgery, when feasible, to completely remove the primary tumor and chemotherapy to control disease spread, even if no evidence of metastasis is present on imaging because most patients have been found to have micrometastasis in studies. Radiotherapy is used to treat most high and intermediate-risk patients as well. The survival of rhabdomyosarcoma patients has improved due to interprofessional collaboration, leading to advancements in diagnosis and management approaches.&#x000a0;This activity for healthcare professionals is designed to enhance the learner's competence when managing rhabdomyosarcoma, equipping them with updated knowledge, skills, and strategies for timely diagnosis and effective interventions, as well as highlighting the role of interprofessional coordination of care, leading to better outcomes for patients and reduced morbidity.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the known histopathologies of rhabdomyosarcoma.</p></list-item><list-item><p>Delineate the recommended evaluation and diagnosis of rhabdomyosarcoma.</p></list-item><list-item><p>Differentiate the treatment options for each rhabdomyosarcoma risk group.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by rhabdomyosarcoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28510&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28510">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28510.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma that is believed to originate from primitive mesenchymal cells that typically differentiate into skeletal tissue. However, these tumors can also arise in other types of tissue and any anatomic area. RMS is the most common soft tissue sarcoma diagnosed in children; only 1% of these cancers are found in adults.<xref ref-type="bibr" rid="article-28510.r1">[1]</xref> The etiology and risk factors remain largely unknown. Most cases of rhabdomyosarcoma are sporadic; however, the disease can be associated with familial syndromes.<xref ref-type="bibr" rid="article-28510.r2">[2]</xref></p>
        <p>Rhabdomyosarcoma is classified into histologic subtypes: embryonal, alveolar, pleomorphic, spindle, and mixed-type. Embryonal is the most commonly occurring subtype and also has the best prognosis.<xref ref-type="bibr" rid="article-28510.r1">[1]</xref>&#x000a0;The management approach is tailored to a patient's risk stratification. Two systems are used to characterize risk stratification for RMS: the Clinical Group or the Stage. Each system uses different factors to categorize patients according to risk, and most authorities use both to determine the most appropriate therapeutic approach. Currently, treatment is multimodal, combining surgery, when feasible, to completely remove the primary tumor and chemotherapy to control disease spread, even if no evidence of metastasis is present on imaging because most patients have been found to have micrometastasis in studies. Radiotherapy is used to treat most high and intermediate-risk patients as well.<xref ref-type="bibr" rid="article-28510.r3">[3]</xref><xref ref-type="bibr" rid="article-28510.r4">[4]</xref>&#x000a0;The survival of rhabdomyosarcoma patients has improved due to interprofessional collaboration, leading to advancements in diagnosis and management approaches. Healthcare professionals should seek to enhance their competence when managing rhabdomyosarcoma. Furthermore, they should have updated knowledge, skills, and strategies for timely diagnosis and effective interventions to improve patient outcomes and reduce morbidity.</p>
      </sec>
      <sec id="article-28510.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Although the etiology of rhabdomyosarcoma&#x000a0;is largely unknown, there is evidence of an underlying genetic component because a chromosomal translocation has been identified in many RMS tumors, and&#x000a0;RMS has been associated with several inherited cancer syndromes (eg, Noonan, Li-Fraumeni, Beckwith-Wiedemann, and Costello.<xref ref-type="bibr" rid="article-28510.r5">[5]</xref><xref ref-type="bibr" rid="article-28510.r6">[6]</xref></p>
        <p>
<bold>Risk Factors</bold>
</p>
        <p>An increased risk of developing RMS is also seen with other factors, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fetal radiation exposure</p>
          </list-item>
          <list-item>
            <p>Parental drug use</p>
          </list-item>
          <list-item>
            <p>Family history of RMS in a first-degree relative</p>
          </list-item>
          <list-item>
            <p>Preterm birth&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Fertility drug use</p>
          </list-item>
          <list-item>
            <p>History of congenital defects&#x000a0;<xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28510.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Rhabdomyosarcoma (RMS) is a rare condition making up 3% of all pediatric cancers. However, RMS is the most common childhood and adolescent soft tissue sarcoma, comprising 50% of soft tissue sarcomas in individuals younger than 20.<xref ref-type="bibr" rid="article-28510.r1">[1]</xref> In the US, there are approximately 350 newly diagnosed patients each year.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref> All histological subtypes of RMS have also been shown to be significantly more prevalent in males.&#x000a0;RMS has a much lower incidence in adults, accounting for approximately 1% of solid cancers.<xref ref-type="bibr" rid="article-28510.r1">[1]</xref></p>
        <p>Although the various subtypes of RMS can arise anywhere in the body, the embryonal histological type is the most common, and the head and neck is the most frequently involved area. RMS involving the extremities is more frequently observed with the alveolar subtype. The pleomorphic and alveolar subtypes&#x000a0;have the highest rates of metastases and, consequently, the poorest prognosis compared to other histologic types. The most common metastatic sites include the lungs, bone marrow, and lymph nodes.<xref ref-type="bibr" rid="article-28510.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-28510.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>
<bold>Gross Pathology</bold>
</p>
        <p>Macroscopically, these tumors usually appear as white to purplish black, necrotic, polypoid infiltrative masses that can be soft or firm to palpation. Tumors may be localized or have metastatic spread; frequently, tumors &#x0003e;5 cm at the time of diagnosis have an increased risk for metastasis.<xref ref-type="bibr" rid="article-28510.r7">[7]</xref><xref ref-type="bibr" rid="article-28510.r8">[8]</xref><xref ref-type="bibr" rid="article-28510.r9">[9]</xref>&#x000a0;Pleomorphic tumors usually are large, well-circumscribed tumors that have minimal to large amounts of necrosis.<xref ref-type="bibr" rid="article-28510.r10">[10]</xref></p>
        <p>
<bold>Histologic Pathology</bold>
</p>
        <p>Myogenesis is the normal process of embryonic cell differentiation into skeletal cells. However, RMS is the result of the abnormal repetition of this process. Therefore, RMS is typically identified when histologic evidence of primitive myogenesis is observed in tumor biopsies. RMS&#x000a0;cells demonstrate little myogenesis, including undifferentiated mesenchymal cells, elongated myoblasts, and poorly differentiated myofibers.<xref ref-type="bibr" rid="article-28510.r11">[11]</xref><xref ref-type="bibr" rid="article-28510.r12">[12]</xref>&#x000a0;Formerly, RMS was divided into 2 primary groups: embryonal and alveolar subtypes due to the histological variation between them. The most recent 2020 WHO classification classifies RMS into 4 main histological subtypes: embryonal, alveolar, spindle or sclerosing cell, and pleomorphic. Some additional variants that had unspecified classifications were included as well.<xref ref-type="bibr" rid="article-28510.r10">[10]</xref><xref ref-type="bibr" rid="article-28510.r1">[1]</xref></p>
        <p>Characteristic histologic findings of RMS tumors include undifferentiated embryonic skeletal cells. Each histologic subtype can usually be differentiated by cell morphology, though there may be some mixed types.<xref ref-type="bibr" rid="article-28510.r1">[1]</xref><xref ref-type="bibr" rid="article-28510.r11">[11]</xref>&#x000a0;Sheets of medium-sized cells arranged in large clusters separated by fibrovascular septa are commonly seen in alveolar&#x000a0;rhabdomyosarcoma. Scattered giant cells are often seen also. Embryonal subtypes typically have small round blue cells and loosely packed rhabdomyoblasts within a myxoid matrix. Spindle cell types are usually arranged in a pseudovascular pattern and are more differentiated than the other subtypes. Pleomorphic subtypes can often be identified due to having undifferentiated cells with a variety of shapes with enlarged hyperchromatic nuclei.<xref ref-type="bibr" rid="article-28510.r13">[13]</xref><xref ref-type="bibr" rid="article-28510.r10">[10]</xref></p>
        <p>The identification of&#x000a0;rhabdomyosarcoma&#x000a0;is sometimes difficult due to the histologic similarity of the tumor to the other small, blue, round-cell pediatric bone and soft tissue tumors (eg, Wilms tumor, lymphoma, small-cell osteosarcoma, and Ewing sarcoma). Therefore, specific immunohistochemistry stains, indicative of skeletal tissue, are usually used to differentiate RMS from other tumor pathologies. Differential diagnoses can be narrowed for tumors with cells with characteristic RMS findings, including positive staining for skeletal markers (eg, myogenin, demin, and Myo-D1) and no differentiation. However, biopsy interpretation can be further complicated because other neoplasms may also exhibit positive marker staining. Therefore, molecular analysis is often used for diagnostic confirmation.<xref ref-type="bibr" rid="article-28510.r11">[11]</xref><xref ref-type="bibr" rid="article-28510.r10">[10]</xref><xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
      </sec>
      <sec id="article-28510.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Rhabdomyosarcoma (RMS) is typically asymptomatic, but depending on tumor features (eg, the site of origin, size, and metastases), patients may present with various symptoms. The most common RMS tumor site is the head, neck, and genitourinary areas. Patients with tumors arising in the head and neck area (eg, orbital, nasopharyngeal, and paranasal sinuses) may present with mucopurulent nasal drainage, sinus congestion, or proptosis. Additionally, symptoms caused by the mass effect of enlarging tumors can occur, including proptosis, dizziness, nausea, or headache.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref>&#x000a0;RMS tumors within the genitourinary area frequently cause symptoms such as vaginal bleeding, pelvic pain, dysuria, hematuria, and urinary frequency. Patients with RMS tumors involving the extremities are typically painless, although patients with pleiomorphic RMS commonly have rapidly growing, painful masses.<xref ref-type="bibr" rid="article-28510.r10">[10]</xref> Physical findings noted on examination also vary according to the anatomical area involved, including cranial nerve palsies, uterine or scrotal enlargement, and bulging vaginal masses. Enlarged lymphatic nodes may be palpated as well if regional spread occurs.<xref ref-type="bibr" rid="article-28510.r14">[14]</xref><xref ref-type="bibr" rid="article-28510.r8">[8]</xref><xref ref-type="bibr" rid="article-28510.r15">[15]</xref><xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
      </sec>
      <sec id="article-28510.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Clinicians should perform initial diagnostic studies following clinical evaluation to identify the underlying etiology of the patient's symptoms or, if present, the visible mass. As with most neoplasms, additional diagnostic evaluation through imaging and tissue biopsy is typically needed for diagnostic confirmation and to determine the extent of spread and prognosis.<xref ref-type="bibr" rid="article-28510.r10">[10]</xref></p>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>MRI imaging of the involved area should initially be used to diagnose patients with a musculoskeletal tumor and&#x000a0;is preferred over CT due to better visualization. Additional imaging studies (eg, CT or PET) can be performed based on possible sites of spread.&#x000a0;Although ultrasound imaging may be acceptable for localized subcutaneous tumors, MRI and CT imaging modalities better characterize soft tissue tumors.<xref ref-type="bibr" rid="article-28510.r16">[16]</xref> Imaging is integral in all patients with musculoskeletal neoplasms because they are typically staged with the TNM system, comprised of physical and radiologic examination findings. Furthermore, imaging studies can be used to assess tumor response to treatment and recurrence. Clinicians also require tumor&#x000a0;assessments by imaging studies to direct biopsies for histological analysis. Therefore, experts recommend imaging&#x000a0;studies should be performed before guided biopsies are obtained because resection of the biopsy tract and the tumor is recommended. Consequently, radiology clinicians, surgeons, and oncologists need close collaboration to evaluate a patient well; pediatric subspecialists should be consulted for pediatric patients.<xref ref-type="bibr" rid="article-28510.r16">[16]</xref><xref ref-type="bibr" rid="article-28510.r17">[17]</xref></p>
        <p>Neoplasm characteristics that are assessed through imaging include size diameters, extent of tissue and lymph node involvement, and distant metastasis. Furthermore, accurate assessment of all the anatomical areas involved is essential as surgeons require this information to perform extensive tumor debulking and prevent recurrent disease.<xref ref-type="bibr" rid="article-28510.r17">[17]</xref><xref ref-type="bibr" rid="article-28510.r16">[16]</xref></p>
        <p>
<bold>Histological and Molecular Analysis Studies</bold>
</p>
        <p>Initial diagnostic studies of RMS involve histological analysis of the mass that assists in identifying the pathology. Biopsies are also essential for staging if a malignancy is diagnosed. The tissue sample may be obtained through an excisional or core needle biopsy. A fine needle biopsy is not recommended because adequate amounts of tissue are unlikely.<xref ref-type="bibr" rid="article-28510.r10">[10]</xref> Because biopsy interpretation can be complicated by other neoplasms that exhibit similar immunohistologic staining, genetic testing, including molecular analysis and fluorescence-in-situ-hybridization testing, is recommended in all patients for diagnostic confirmation and identification of RMS subtypes.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref><xref ref-type="bibr" rid="article-28510.r10">[10]</xref></p>
        <p>Embryonal RMS has been associated with aneuploidies of the&#x000a0;<italic toggle="yes">RAS</italic>&#x000a0;and <italic toggle="yes">TP53&#x000a0;</italic>genes, while&#x000a0;alveolar RMS was found in studies to have two distinguishing chromosomal translocations, t(2;13)(q35;q14), which is more common, and t(1;13)(p36;q14).<xref ref-type="bibr" rid="article-28510.r18">[18]</xref><xref ref-type="bibr" rid="article-28510.r10">[10]</xref>&#x000a0;Furthermore, genetic analysis has found the genetic fusions&#x000a0;<italic toggle="yes">PAX3::FOXO1</italic>&#x000a0;and&#x000a0;<italic toggle="yes">PAX7::FOXO1</italic>&#x000a0;to be associated with these chromosomal translocations. Therefore, alveolar RMS can be more accurately diagnosed using molecular analysis.&#x000a0;Spindle cell and sclerosing subtypes have been found to have various gene fusions involving&#x000a0;<italic toggle="yes">NCOA2</italic>&#x000a0;and&#x000a0;<italic toggle="yes">VGLL2</italic>. Some genetic mutations of <italic toggle="yes">MYOD1&#x000a0;</italic>have also been identified.<xref ref-type="bibr" rid="article-28510.r10">[10]</xref>&#x000a0;Pleomorphic RMS, primarily seen in adults, has been found to have a wide range of genetic alterations.<xref ref-type="bibr" rid="article-28510.r10">[10]</xref>&#x000a0;Histologic and genetic identification of RMS subtypes also assists clinicians with determining a patient's prognosis. For instance, sclerosing and spindle cell types typically have an excellent prognosis; however, some mutations of this subtype and all pleomorphic types have a poor prognosis.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref><xref ref-type="bibr" rid="article-28510.r10">[10]</xref></p>
      </sec>
      <sec id="article-28510.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>In the US, the management approach is tailored to a patient's risk stratification. Two systems are used to characterize risk stratification for RMS: the Clinical Group or the Stage. Each system uses different factors to categorize patients according to risk, and most authorities use both to determine the most appropriate therapeutic approach.&#x000a0;The RMS Stage utilizes categories 1 to 4 with risk stratification determined by tumor characteristics&#x000a0;(eg, size, extension, and location), lymph node involvement, and distant metastasis (TMN).<xref ref-type="bibr" rid="article-28510.r4">[4]</xref>&#x000a0;Clinical Group utilizes 4 categories, from I to IV, and differentiates risk by surgical pathology, including:<xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Completeness of resection</p>
          </list-item>
          <list-item>
            <p>Presence or absence of residual disease at the margins</p>
          </list-item>
          <list-item>
            <p>Evidence of distant metastasis</p>
          </list-item>
        </list>
        <p>Based on these factors, patients are placed into one of the following risk groups: low, intermediate, or high. In Europe, slightly different features are used to determine risk stratification.<xref ref-type="bibr" rid="article-28510.r3">[3]</xref>&#x000a0;Currently, treatment is multimodal, combining surgery, when feasible, to completely remove the primary tumor and chemotherapy to control disease spread, even if no evidence of metastasis is present on imaging because most patients have been found to have micrometastasis in studies. Radiotherapy is used to treat most high and intermediate-risk patients as well.<xref ref-type="bibr" rid="article-28510.r3">[3]</xref><xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
        <p>The chemotherapy regimen used in the US for the treatment of RMS is comprised of vincristine, actinomycin D, and cyclophosphamide (VAC), usually in 3-week cycles; in Europe, a different regimen is used, consisting of ifosfamide, vincristine, and actinomycin D (IVA). Studies have shown both regimens to have comparable outcomes.<xref ref-type="bibr" rid="article-28510.r3">[3]</xref><xref ref-type="bibr" rid="article-28510.r4">[4]</xref>&#x000a0;For high- to intermediate-risk patients, chemotherapy is typically given for 6 to 9 months; in low-risk patients, chemotherapy is shortened to approximately 24 months, and dosages may also be reduced.<xref ref-type="bibr" rid="article-28510.r3">[3]</xref><xref ref-type="bibr" rid="article-28510.r4">[4]</xref>&#x000a0;Some experts recommend repeat imaging to assess tumor response to chemotherapy after 3 cycles.<xref ref-type="bibr" rid="article-28510.r16">[16]</xref></p>
        <p>Recommendations concerning continued surveillance imaging for recurrent disease also vary between Europe and the US. Current guidelines in Europe recommend surveillance imaging every 4 months for 2 years. In the US, there are no set guidelines; however, most clinicians follow current Children's Oncology Group recommendations to repeat imaging every 4 months for 4 years. Due to known complications from radiation exposure, particularly in children, many experts have recently advocated for US clinicians to adopt European surveillance guidelines as both protocols have similar outcomes.&#x000a0;The management of patients with RMS is continuously evolving as new, evidence-based results emerge from clinical trials of treatment advancements.<xref ref-type="bibr" rid="article-28510.r19">[19]</xref></p>
      </sec>
      <sec id="article-28510.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other musculoskeletal neoplasms that should be excluded include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ewing sarcoma</p>
          </list-item>
          <list-item>
            <p>Li-Fraumeni syndrome</p>
          </list-item>
          <list-item>
            <p>Lipomas</p>
          </list-item>
          <list-item>
            <p>Liposarcoma</p>
          </list-item>
          <list-item>
            <p>Lymphadenopathy</p>
          </list-item>
          <list-item>
            <p>Lymphoproliferative disorders</p>
          </list-item>
          <list-item>
            <p>Neurofibromatosis type 1</p>
          </list-item>
          <list-item>
            <p>Osteosarcoma</p>
          </list-item>
          <list-item>
            <p>Wilms tumor&#x000a0;<xref ref-type="bibr" rid="article-28510.r11">[11]</xref><xref ref-type="bibr" rid="article-28510.r10">[10]</xref><xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28510.s10" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>
<bold>Surgical Resection</bold>
</p>
        <p>Surgical treatment of RMS is primarily used for histologic diagnosis and risk stratification.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref> However, because complete tumor removal is an integral part of risk stratification, surgery in combination with chemotherapy and radiation remains an essential aspect of multimodal RMS treatment for many patients. In general, surgical excision of the primary tumor site is recommended if complete excision without disfigurement or decreased function is possible. However, for some sites, tumor resection is difficult due to the risk of causing mutilation of surrounding tissue. With the introduction of effective chemotherapeutic regimens, modern surgical techniques are less radical and emphasize long-term functional preservation. For some patients, definitive surgical excision is frequently performed after several cycles of chemotherapy to decrease the need for extensive or disfiguring surgery, termed delayed primary excision.<xref ref-type="bibr" rid="article-28510.r18">[18]</xref>&#x000a0;Adequate margins are defined as a 5mm ring of normal tissue surrounding the tumor.<xref ref-type="bibr" rid="article-28510.r21">[21]</xref>&#x000a0;Patients with clear margins following primary tumor resection have higher survival rates than those with grossly positive margins (ie, group 3 or 4) after resection.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref>&#x000a0;Other than for RMS tumors in the head and neck area, lymph node sampling as part of initial surgical resection is recommended to determine risk stratification.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref><xref ref-type="bibr" rid="article-28510.r22">[22]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Head and neck</bold>:&#x000a0;RMS of the head and neck, particularly in the parameningeal areas (eg, the nasal cavity, nasopharynx, and paranasal sinus), are typically considered unfavorable sites for resection. Currently, treatment primarily utilizes chemotherapy, with surgery only performed for biopsies or recurrent disease.<xref ref-type="bibr" rid="article-28510.r23">[23]</xref>&#x000a0;There are limited studies of localized RMS in nonparameningeal areas&#x000a0;that showed beneficial results with using surgical excision and radiotherapy; however, these studies were too small to reach any conclusions.<xref ref-type="bibr" rid="article-28510.r24">[24]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Extremities</bold>:&#x000a0;RMS of the extremities carries a poorer prognosis than other disease sites. Resection should be done to preserve limb function and ensure complete resection. As with other tumor locations, incomplete resections portend a poorer outcome and require more intensive treatment. Therefore, if complete&#x000a0;resection can be performed without functional or cosmetic impairment, then excision should be performed before chemotherapy; however, if complete resection is not possible, chemotherapy followed by excision is recommended. As it has a prognostic and therapeutic role, regional and sentinel lymph nodes should be assessed by imaging and histologic analysis.<xref ref-type="bibr" rid="article-28510.r25">[25]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Paratesticular area</bold>:&#x000a0;Radical surgical resection via an inguinal orchiectomy, including the entire spermatic cord, is the standard of care for paratesticular RMS. Testicular preservation is not recommended. As with other testicular tumors, a trans-scrotal resection is strongly discouraged due to difficulty achieving complete excision with that approach. Patients with microscopically positive cord margins after the initial resection should undergo repeated excision before chemotherapy. Furthermore, due to the risk of nodal metastasis, retroperitoneal lymph node dissection (RPLND) is recommended for patients with paratesticuar RMS and any of the following:<xref ref-type="bibr" rid="article-28510.r26">[26]</xref>
<list list-type="bullet"><list-item><p>Older than the age of 10</p></list-item><list-item><p>Alveolar RMS on histology</p></list-item><list-item><p>Lymph nodes &#x0003e;1 cm on imaging</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Genitourinary area</bold>:&#x000a0;Typically, RMS tumors of the bladder and prostate have a poorer prognosis than other RMS sites due to being unfavorable for complete resection. However, RMS tumors involving the female pelvic organs (eg, vagina, uterus, and vulva) are more favorable for complete resection and have a better prognosis.<xref ref-type="bibr" rid="article-28510.r7">[7]</xref><xref ref-type="bibr" rid="article-28510.r27">[27]</xref>&#x000a0;Generally, genitourinary RMS tumors are biopsy-confirmed, initially treated with chemotherapy to reduce tumor size, and then surgically excised.<xref ref-type="bibr" rid="article-28510.r28">[28]</xref><xref ref-type="bibr" rid="article-28510.r22">[22]</xref>&#x000a0;In some patients, brachytherapy may be beneficial as well.<xref ref-type="bibr" rid="article-28510.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Metastatic Disease</bold>
</p>
        <p>Distant metastatic disease is identified in approximately 20% of children at their initial diagnosis. Metastasis is a common finding secondary to lymphatic and hematogenous spread of RMS, with the most frequent areas of space being the lungs, bones, and bone marrow.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref>&#x000a0;The overall survival of patients with metastatic&#x000a0;rhabdomyosarcoma is meager, reported to be &#x0003c;20%.<xref ref-type="bibr" rid="article-28510.r5">[5]</xref>&#x000a0;Treatment of metastase sites has not proved to be beneficial. However, some European studies have demonstrated improved survival in patients who underwent a combination of resection and radiotherapy to aggressively treat the primary tumor despite metastasis.<xref ref-type="bibr" rid="article-28510.r5">[5]</xref></p>
        <p>
<bold>Second-Look Surgery</bold>
</p>
        <p>Second-look surgeries are controversial but may be used to assess tumor response and determine candidacy for reduced dose radiation. Studies have not demonstrated any benefits to overall survival; however, outcomes have been improved secondary to radiotherapy adjustments. Therefore, many experts recommend interprofessional communication and collaboration to tailor management decisions to each patient.<xref ref-type="bibr" rid="article-28510.r30">[30]</xref><xref ref-type="bibr" rid="article-28510.r31">[31]</xref></p>
      </sec>
      <sec id="article-28510.s11" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>
<bold>Radiation Therapy Indications</bold>
</p>
        <p>In the US, most patients with RMS are treated with a multimodal approach that combines chemotherapy, surgical excision, and radiation therapy (RT). Some patients classified as low-risk and with clear margins following resection may not require radiation; most others do, though the dose required is adjusted according to their risk group and the residual disease present following initial resection.<xref ref-type="bibr" rid="article-28510.r32">[32]</xref>&#x000a0;In Europe, RT was historically avoided due to associated risks, particularly in children who are more likely to experience adverse effects on growth. However, due to the significantly improved survival, clinicians have increasingly utilized this modality.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref></p>
        <p>RT is primarily indicated for localized disease control, which significantly impacts survival. Additionally, RT is preferred by some experts for any involved lymph nodes, as therapeutic lymph node dissection is not recommended.&#x000a0;Radiotherapy can be delivered with various methods, including external beam radiation, intensity-modulated radiation, proton therapy, and brachytherapy. Brachytherapy may be preferred in select circumstances, including gynecologic and head and neck tumors, due to the ability to target treatment on the tumor without damaging the surrounding normal tissue as much.<xref ref-type="bibr" rid="article-28510.r18">[18]</xref>&#x000a0;Because of the various factors that need to be considered when deciding on the approach to RT, the treatment strategy employed is usually decided upon by the radiation oncologist in collaboration with the multidisciplinary team.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref><xref ref-type="bibr" rid="article-28510.r18">[18]</xref></p>
        <p>
<bold>Radiation Therapy Planning and Dosing</bold>
</p>
        <p>The tumor volume to be treated and the RT dosage are typically determined by CT imaging in slices with a 2 to 3 mm thick standard thickness. However,&#x000a0;other imaging modalities (eg, MRI or PET) may be utilized.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref>&#x000a0;Generally, the planned tumor volume to be treated is obtained from CT or MRI imaging of the RMS tumor&#x000a0;before any surgical resection or chemotherapy and involves all gross primary and nodal diseases called the gross target volume (GTV). The clinical target volume (CTV) comprises the GTV and an additional 1 cm of tissue surrounding the tumor in case of marginal microscopic disease. The CTV is used to calculate the RT dosage needed.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref>&#x000a0;RT guidelines recommend giving RT in fractionated doses of 1.8 Gy daily until the maximum total amount is reached.<xref ref-type="bibr" rid="article-28510.r33">[33]</xref>&#x000a0;Table 1 shows the standard RT doses the Children's Oncology Group (COG) used.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref></p>
        <table-wrap id="article-28510.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Standard Radiation Therapy Dosages Utilized by the Children's Oncology Group&#x000a0;[20]</title>
          </caption>
          <table style="width: 821px;">
            <tbody>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p><bold>Indication</bold></p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p><bold>&#x000a0;Clinical Group</bold></p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p><bold>&#x000a0;Stage</bold></p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<p><bold>&#x000a0;Dose</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p>Completely Resected (R0) node-negative disease</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;I</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;1 to 3</p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<p>&#x000a0;0 Gy</p>
</td>
              </tr>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p>Microscopic positive margins</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;I</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;1 to 3</p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<p>&#x000a0;36 Gy</p>
</td>
              </tr>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p>Fusion-positive RMS</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;II</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;1 to 3</p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<p>&#x000a0;36 Gy</p>
</td>
              </tr>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p>Resected node-positive disease</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;II</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;1 to 3</p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<p>&#x000a0;41.4 Gy</p>
</td>
              </tr>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p>RMS of the Orbit</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;III</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;1</p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>45 Gy if a complete response to chemotherapy is noted</p></list-item><list-item><p>50.4Gy if a partial response to chemotherapy is noted</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p>Gross residual disease (R2 resection) &#x0003c;5 cm at diagnosis</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;III</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;1 to 3</p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<p>&#x000a0;50.4 Gy</p>
</td>
              </tr>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p>Gross residual disease (R2 resection) &#x0003e;5 cm at diagnosis</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;III</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;1 to 3</p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<p>&#x000a0;59.4 Gy</p>
</td>
              </tr>
              <tr>
                <td style="width: 423px;" rowspan="1" colspan="1">
<p>Lung Metastasis</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;IV</p>
</td>
                <td style="width: 423.4px;" rowspan="1" colspan="1">
<p>&#x000a0;4</p>
</td>
                <td style="width: 382.6px;" rowspan="1" colspan="1">
<p>15 Gy to the whole lung&#x000a0;</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Timing of Therapy</bold>
</p>
        <p>In all patients receiving RT, the Children's Oncology Group (COG) recommends beginning treatment after 4 cycles (ie, 12 weeks) of chemotherapy. Most localized recurrence of RMS has been observed in patients who did not receive RT or treatment was delayed past 24 weeks after starting chemotherapy.&#x000a0;RT is typically only omitted for low-risk patients with completely resected fusion-negative tumors. However, the optimal time to initiate RT has yet to be determined.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref>&#x000a0;Some European guidelines recommend repeated CT or MRI imaging for RT planning after 6 cycles of chemotherapy have been completed. However, as there is no consensus on the optimal RT treatment strategy, radiation treatment is usually determined by the&#x000a0;radiation oncologist in collaboration with the multidisciplinary team.<xref ref-type="bibr" rid="article-28510.r18">[18]</xref></p>
        <p>
<bold>Radiation Therapy Complications&#x000a0;</bold>
</p>
        <p>While acute toxicities can be problematic, late radiation toxicities can have long-lasting effects on a patient's quality of life.&#x000a0;As a result, there have been several studies to minimize radiation dose or omit radiation altogether. Late effects, which can vary according&#x000a0;to location and dose of RT, are a significant consideration in children and adolescents due to longer life expectancies. Furthermore, younger children have the greatest risk for late-onset adverse effects, with some studies demonstrating the dose effect to be the most pronounced in children ages 2 to 10. Because the mitotically active growth plate region in children is susceptible to radiation, alterations in stature, fibrosis, and limb atrophy can be seen in 80% of children. However, late effects may take up to 10 years to become evident.<xref ref-type="bibr" rid="article-28510.r34">[34]</xref><xref ref-type="bibr" rid="article-28510.r35">[35]</xref>&#x000a0;As a result, RT doses &#x0003e;10 Gy should be avoided in children.<xref ref-type="bibr" rid="article-28510.r36">[36]</xref>&#x000a0;Late sequelae secondary to RT include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurocognitive impairment&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Facial disfigurement (eg, facial bone hypoplasia)</p>
          </list-item>
          <list-item>
            <p>Endocrinopathies (eg,&#x000a0;growth hormone deficiency, diabetes, central hypothyroidism, and ACTH deficiency)</p>
          </list-item>
          <list-item>
            <p>Ocular impairment (eg,&#x000a0;cataracts, amblyopia, retinopathy, and decreased visual acuity)</p>
          </list-item>
          <list-item>
            <p>Nasal and oral complications (eg, odynophagia, chronic sinusitis, epistaxis, mucositis, and&#x000a0;delayed tooth eruption)</p>
          </list-item>
          <list-item>
            <p>Dermatitis</p>
          </list-item>
          <list-item>
            <p>Intestinal obstruction</p>
          </list-item>
          <list-item>
            <p>Chronic otitis and hearing loss</p>
          </list-item>
          <list-item>
            <p>Urinary incontinence and frequency</p>
          </list-item>
          <list-item>
            <p>Vaginal stenosis</p>
          </list-item>
          <list-item>
            <p>Erectile dysfunction</p>
          </list-item>
          <list-item>
            <p>Joint stiffness and impaired mobility</p>
          </list-item>
          <list-item>
            <p>Skeletal growth impairment and pathological fractures</p>
          </list-item>
          <list-item>
            <p>Secondary malignancy&#x000a0;<xref ref-type="bibr" rid="article-28510.r4">[4]</xref><xref ref-type="bibr" rid="article-28510.r32">[32]</xref><xref ref-type="bibr" rid="article-28510.r37">[37]</xref><xref ref-type="bibr" rid="article-28510.r36">[36]</xref><xref ref-type="bibr" rid="article-28510.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28510.s12" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>
<bold>Chemotherapy Indications</bold>
</p>
        <p>Chemotherapy is indicated for all patients with RMS of any risk category. Frequently, micrometastasis is found in low-risk patients; therefore, chemotherapy is recommended for all patients, even when imaging appears normal.<xref ref-type="bibr" rid="article-28510.r18">[18]</xref>&#x000a0;Treatment with chemotherapy has increased overall survival to &#x0003e;70%.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref> Additionally, chemotherapy has been found to decrease the risk of disease progression by 48%.<xref ref-type="bibr" rid="article-28510.r24">[24]</xref>&#x000a0;Therefore, multiagent chemotherapy's effectiveness in treating RMS in all patients is well established.</p>
        <p>
<bold>Chemotherapy Timing and Duration</bold>
</p>
        <p>&#x000a0;For the vast majority of patients, chemotherapy is given as the first line of treatment for multiple cycles, which is then paused for interval treatment with surgery and/or RT, followed by the resumption of chemotherapy. The specific agents used in the standard protocols vary between the US and Europe, although clinical outcomes are similar. In the US, the multiagent chemotherapy most commonly utilized is vincristine, actinomycin D, and cyclophosphamide (VAC) for 9 to 12 cycles initially.<xref ref-type="bibr" rid="article-28510.r32">[32]</xref><xref ref-type="bibr" rid="article-28510.r20">[20]</xref>&#x000a0;Vincristine inhibits microtubule polymerization. Actinomycin D inhibits DNA transcription, and cyclophosphamide is an alkylating agent.<xref ref-type="bibr" rid="article-28510.r38">[38]</xref>&#x000a0;Europe, however, commonly uses 4 cycles of ifosfamide, vincristine, and actinomycin D (IVA) followed by 5 cycles of&#x000a0;vincristine and actinomycin D for intermediate-risk patients initially, while 9 cycles of IVA are recommended in high-risk patients. In low-risk patients, 8&#x000a0;cycles of vincristine and actinomycin D are typically recommended.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref></p>
        <p>The total duration of chemotherapy varies depending on a patient's risk stratification and which protocol their clinician is following.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref>&#x000a0;Currently, the total duration used by the COG in the US is 24 to 48 weeks; in Europe, the duration is much less, totaling 22 to 27 weeks. There is no consensus on dosage recommendation either, with various studies using an alkylating agent dose ranging from 1&#x000a0;g/m<sup>2</sup> per&#x000a0;course to 2.2&#x000a0;g/m<sup>2</sup> per&#x000a0;course.<xref ref-type="bibr" rid="article-28510.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>Recurrent Disease</bold>
</p>
        <p>The majority of deaths related to RMS occur within the first 2 years. Outcomes are generally poor, with a median survival time of 9.6 months and a 5-year overall survival of 28%.<xref ref-type="bibr" rid="article-28510.r39">[39]</xref><xref ref-type="bibr" rid="article-28510.r40">[40]</xref>&#x000a0;&#x000a0;At present, there is no established standard treatment for RMS relapse because patient survival remains poor even after chemotherapy treatment.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
        <p>
<bold>Chemotherapy Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Secondary malignancies</bold>:&#x000a0;The risk of secondary malignancies increases with certain chemotherapies and radiotherapy compared to surgery alone.<xref ref-type="bibr" rid="article-28510.r41">[41]</xref> Alkylating agents (eg, cyclophosphamide) may contribute to the development of hematologic malignancies such as acute myeloid leukemia.<xref ref-type="bibr" rid="article-28510.r42">[42]</xref> The addition of etoposide appears to increase this risk significantly.<xref ref-type="bibr" rid="article-28510.r42">[42]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hemorrhagic cystitis</bold>:&#x000a0;The use of cyclophosphamide and ifosfamide is the primary cause of hemorrhagic cystitis in patients treated with those agents. Acrolein, a metabolite of both cyclophosphamide and ifosfamide, is thought to accumulate in the bladder, generating a reactive oxygen species that damages and destroys cells.<xref ref-type="bibr" rid="article-28510.r43">[43]</xref> The relative risk corresponds with the total cumulative dose received. Mesna is typically given prophylactically to reduce the risk of hemorrhagic cystitis by binding to acrolein, allowing the harmless byproduct to be excreted in the urine. Other methods, including hyperhydration, may be equally effective.<xref ref-type="bibr" rid="article-28510.r44">[44]</xref><xref ref-type="bibr" rid="article-28510.r45">[45]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Infertility</bold>:&#x000a0;Alkylating agents such as cyclophosphamide can also lead to infertility in men due to dose-dependent adverse effects on seminiferous tubules. Testosterone production may also be impaired, leading to reduced fertility.<xref ref-type="bibr" rid="article-28510.r46">[46]</xref>&#x000a0;Exposure before puberty is not protective.<xref ref-type="bibr" rid="article-28510.r47">[47]</xref> For females, ovarian failure appears to be dose and age-dependent, with only higher doses inducing ovarian failure in younger women.<xref ref-type="bibr" rid="article-28510.r48">[48]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Neurotoxicity</bold>:&#x000a0;Peripheral neuropathy is one of the most common adverse effects associated with vincristine, though the severity appears to vary with dose, age, drug clearance, and race.<xref ref-type="bibr" rid="article-28510.r49">[49]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28510.s13" sec-type="Staging">
        <title>Staging</title>
        <p>The 2 classification systems utilized in managing rhabdomyosarcoma are the TNM (tumor, nodes, metastasis) Staging system and the Clinical Group (CG) system. These systems complement each other and are used to assess prognosis and guide treatment for patients with rhabdomyosarcoma. The RMS prognostic stratification classifies patients based on these systems as low, intermediate, or high risk.&#x000a0;</p>
        <p>
<bold>The Rhabdomyosarcoma&#x000a0;Risk Stratification Systems</bold>
</p>
        <p>In general, the RMS Clinical Group (CG) system&#x000a0;(see&#x000a0;<bold>Table 2.</bold>&#x000a0;RMS&#x000a0;Clinical Group Classification)&#x000a0;differentiates risk by surgical pathology, including:<xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Completeness of resection</p>
          </list-item>
          <list-item>
            <p>Presence or absence of residual disease at the margins</p>
          </list-item>
          <list-item>
            <p>Evidence of distant metastasis</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Table 2. </bold>RMS&#x000a0;Clinical Group Classification&#x000a0;<xref ref-type="bibr" rid="article-28510.r7">[7]</xref><xref ref-type="bibr" rid="article-28510.r20">[20]</xref></p>
        <table-wrap id="article-28510.table1" position="float" orientation="portrait">
          <table style="width: 824px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 371.725px;" rowspan="1" colspan="1">
<bold>Initial Surgical Pathology</bold>
</td>
                <td style="width: 385.275px;" rowspan="1" colspan="1">
<bold>Clinical Group</bold>
</td>
              </tr>
              <tr>
                <td style="width: 371.725px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Localized tumor</p></list-item><list-item><p>Anatomically confined to the site of origin</p></list-item><list-item><p>Tumor completely resected</p></list-item></list>
</td>
                <td style="width: 385.275px;" rowspan="1" colspan="1">IA</td>
              </tr>
              <tr>
                <td style="width: 371.725px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Localized tumor</p></list-item><list-item><p>Not anatomically confined to the site of origin</p></list-item><list-item><p>Tumor completely resected</p></list-item></list>
</td>
                <td style="width: 385.275px;" rowspan="1" colspan="1">IB</td>
              </tr>
              <tr>
                <td style="width: 371.725px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Tumor completely grossly resected</p></list-item><list-item><p>Microscopically positive margins</p></list-item></list>
</td>
                <td style="width: 385.275px;" rowspan="1" colspan="1">IIA</td>
              </tr>
              <tr>
                <td style="width: 371.725px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Tumor completely grossly resected</p></list-item><list-item><p>Microscopically negative margins</p></list-item><list-item><p>Positive spread to regional lymph nodes or another organ</p></list-item></list>
</td>
                <td style="width: 385.275px;" rowspan="1" colspan="1">IIB</td>
              </tr>
              <tr>
                <td style="width: 371.725px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Tumor completely grossly resected</p></list-item><list-item><p>Microscopically positive margins</p></list-item><list-item><p>Positive spread to regional lymph nodes</p></list-item></list>
</td>
                <td style="width: 385.275px;" rowspan="1" colspan="1">IIC</td>
              </tr>
              <tr>
                <td style="width: 371.725px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Localized extensive tumor</p></list-item><list-item><p>Gross residual disease after attempted resection or biopsy only</p></list-item></list>
</td>
                <td style="width: 385.275px;" rowspan="1" colspan="1">III</td>
              </tr>
              <tr>
                <td style="width: 371.725px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Gross residual disease with metastasis&#x000a0;</p></list-item></list>
</td>
                <td style="width: 385.275px;" rowspan="1" colspan="1">IV</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The RMS Stage classification (see&#x000a0;<bold>Table 3.</bold>&#x000a0;RMS Staging)&#x000a0;is primarily based on the following factors:<xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Tumor characteristics (eg, size and extension)</p>
          </list-item>
          <list-item>
            <p>Lymph nodes involvement</p>
          </list-item>
          <list-item>
            <p>Distant metastases</p>
          </list-item>
          <list-item>
            <p>Favorable or unfavorable location
<list list-type="bullet"><list-item><p>Favorable sites: biliary tract, orbit, nonparameningeal head and neck, and genitourinary areas other than the prostate and bladder</p></list-item><list-item><p>Unfavorable sites:&#x000a0;parameningeal areas, prostate, bladder, and extremities</p></list-item></list>
</p>
          </list-item>
        </list>
        <table-wrap id="article-28510.table2" position="float" orientation="portrait">
          <caption>
            <title>Table 3.&#x000a0;RMS Staging&#x000a0;[20][7]</title>
          </caption>
          <table style="width: 826px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 380.725px;" rowspan="1" colspan="1">Stage 1</td>
                <td style="width: 378.275px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Favorable tumor site</p></list-item><list-item><p>Confined to the site of origin or some extension into surrounding tissue</p></list-item><list-item><p>Regional lymph node status involved, uninvolved, or unknown</p></list-item><list-item><p>Any size tumor</p></list-item><list-item><p>No distant metastasis</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 380.725px;" rowspan="1" colspan="1">Stage 2</td>
                <td style="width: 378.275px;" rowspan="1" colspan="1">&#x000a0;
<list list-type="bullet"><list-item><p>Unfavorable tumor site</p></list-item><list-item><p>Confined to the site of origin or some extension into surrounding tissue</p></list-item><list-item><p>Regional lymph node status uninvolved or unknown</p></list-item><list-item><p>Tumor size &#x02264;5 cm</p></list-item><list-item><p>No distant metastasis</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 380.725px;" rowspan="1" colspan="1">Stage 3</td>
                <td style="width: 378.275px;" rowspan="1" colspan="1">&#x000a0;
<list list-type="bullet"><list-item><p>Unfavorable tumor site</p></list-item><list-item><p>Confined to the site of origin or some extension into surrounding tissue</p></list-item><list-item><p>Regional lymph node status involved</p></list-item><list-item><p>Tumor size &#x02264;5 cm</p></list-item><list-item><p>No distant metastasis</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 380.725px;" rowspan="1" colspan="1">Stage 3</td>
                <td style="width: 378.275px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Unfavorable tumor site</p></list-item><list-item><p>Confined to the site of origin or some extension into surrounding tissue</p></list-item><list-item><p>Regional lymph node status involved, uninvolved, or unknown</p></list-item><list-item><p>Tumor size &#x0003e;5 cm</p></list-item><list-item><p>No distant metastasis</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 380.725px;" rowspan="1" colspan="1">Stage 4</td>
                <td style="width: 378.275px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Any tumor site of any size and any lymph node involvement</p></list-item><list-item><p>Positive metastatic spread</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Rhabdomyosarcoma Risk Groups</bold>
</p>
        <p>Risk stratification is essential to determine a patient's prognosis and direct treatment. The risk stratification that is used in Europe was developed by the European Paediatric Soft Tissue Sarcoma Group. Though similar to the risk groups used in the US, the European also incorporates patient age and tumor histology to stratify patients into 4 categories: low, standard, high, and very high risk.&#x000a0;In the US, clinicians primarily use the Children's Oncology Group (COG) risk stratification, which integrates&#x000a0;<italic toggle="yes">FOXO1</italic>::<italic toggle="yes">PAX</italic>&#x000a0;fusion status and the RMS grouping and staging systems to stratify patients into 3 main groups with the low-risk group made up of 2 subsets.<xref ref-type="bibr" rid="article-28510.r20">[20]</xref></p>
        <p>
<bold>Low-risk subset 1</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1 or 2, CG I to III, fusion-negative&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Stage 1, CG III, orbital site only, fusion-negative</p>
          </list-item>
        </list>
        <p>
<bold>Low-risk subset 2</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1, CG III, nonorbital site, fusion-negative</p>
          </list-item>
          <list-item>
            <p>Stage 3, CG I or II, fusion negative</p>
          </list-item>
        </list>
        <p>
<bold>Intermediate-risk</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 2 or 3, CG III, fusion negative</p>
          </list-item>
          <list-item>
            <p>Stage 4, CG IV, patient age &#x0003c;10 years, fusion-negative</p>
          </list-item>
          <list-item>
            <p>Stage 1 to 3, CG I to III, fusion-positive</p>
          </list-item>
        </list>
        <p>
<bold>High-risk</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage IV, CG IV, any fusion status</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28510.s14" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>RMS prognosis depends on multiple factors that include clinical and histopathologic characteristics. Localized favorable site disease tends to have the best 5-year overall survival of approximately 90%.<xref ref-type="bibr" rid="article-28510.r50">[50]</xref> The overall survival of patients with metastatic RMS is very low, reported to be &#x0003c;20%.<xref ref-type="bibr" rid="article-28510.r5">[5]</xref> Adults have a much poorer 5-year&#x000a0;overall survival when compared with children (27% versus 61%). Parameningeal RMS and RMS of the extremities tend to have a poor prognosis compared to other sites.<xref ref-type="bibr" rid="article-28510.r51">[51]</xref>&#x000a0;The prognosis for recurrent RMS is also very poor, and optimal management is still being studied. Similar to an initial diagnosis of RMS, the overall survival with recurrent RMS is based on various factors, including the original tumor stage and the tumor recurrence site and histology.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
      </sec>
      <sec id="article-28510.s15" sec-type="Complications">
        <title>Complications</title>
        <p>There is little research into the quality of life patients have following successful treatment for RMS. The limited studies available have demonstrated that survivors of genitourinary RMS, in particular, may have ongoing issues such as urinary incontinence, urinary frequency, and erectile dysfunction.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref>&#x000a0;Chemotherapy and radiotherapy, particularly in children, may cause complications at RMS treatment sites that clinicians should be aware of, including:<xref ref-type="bibr" rid="article-28510.r16">[16]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurocognitive impairment&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Facial disfigurement (eg, facial bone hypoplasia)</p>
          </list-item>
          <list-item>
            <p>Endocrinopathies (eg,&#x000a0;growth hormone deficiency, diabetes, central hypothyroidism, and ACTH deficiency)</p>
          </list-item>
          <list-item>
            <p>Ocular impairment (eg,&#x000a0;cataracts, amblyopia, retinopathy, and decreased visual acuity)</p>
          </list-item>
          <list-item>
            <p>Nasal and oral complications (eg, odynophagia, chronic sinusitis, epistaxis, mucositis, and&#x000a0;delayed tooth eruption)</p>
          </list-item>
          <list-item>
            <p>Dermatitis</p>
          </list-item>
          <list-item>
            <p>Intestinal obstruction</p>
          </list-item>
          <list-item>
            <p>Chronic otitis and hearing loss</p>
          </list-item>
          <list-item>
            <p>Urinary incontinence and frequency</p>
          </list-item>
          <list-item>
            <p>Vaginal stenosis</p>
          </list-item>
          <list-item>
            <p>Erectile dysfunction</p>
          </list-item>
          <list-item>
            <p>Joint stiffness and impaired mobility</p>
          </list-item>
          <list-item>
            <p>Skeletal growth impairment and pathological fractures</p>
          </list-item>
          <list-item>
            <p>Secondary malignancy&#x000a0;<xref ref-type="bibr" rid="article-28510.r4">[4]</xref><xref ref-type="bibr" rid="article-28510.r32">[32]</xref><xref ref-type="bibr" rid="article-28510.r37">[37]</xref><xref ref-type="bibr" rid="article-28510.r36">[36]</xref><xref ref-type="bibr" rid="article-28510.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28510.s16" sec-type="Consultations">
        <title>Consultations</title>
        <p>The diagnosis and management of RMS require the involvement of a multidisciplinary team. Radiology clinicians must be consulted to obtain imaging studies that provide the primary care clinicians and oncology physicians with the necessary information to stage a patient with RMS correctly. Oncology clinicians then may collaborate with the other health team members to determine a patient's prognosis and specific treatment protocol.&#x000a0;Orthopedic oncologists and neurosurgeons may also need to be consulted if the bone, spine, or brain are involved.<xref ref-type="bibr" rid="article-28510.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-28510.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Since the etiology of RMS is mostly unknown, optimal prevention strategies have yet to be determined. However, because the association between RMS and cancer syndromes has been demonstrated, some experts have proposed that laboratory and imaging studies may be used to monitor individuals with RMS-associated cancers (eg, Li-Fraumeni syndrome) to attempt to diagnose RMS earlier.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
      </sec>
      <sec id="article-28510.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Early diagnosis is critical to reducing the mortality of rhabdomyosarcoma. Individuals with delayed diagnoses were found to have a much higher incidence of advanced-stage cancers and increasingly poor outcomes. Therefore, interprofessional collaboration that increases access to diagnostic and treatment resources, improves communication, and advances clinician expertise will significantly reduce diagnostic delays and improve patient outcomes.<xref ref-type="bibr" rid="article-28510.r4">[4]</xref></p>
        <p>Furthermore, diagnosis and management of RMS require the involvement of a multidisciplinary team. When the primary care provider, nurse practitioner, or internist has a patient diagnosed with rhabdomyosarcoma, referral to an oncologist is vital to developing an effective treatment protocol. Radiology clinicians must be consulted to obtain imaging studies that provide the primary care clinicians and oncology physicians with the necessary information to stage a patient with RMS correctly.&#x000a0;The management of these malignant lesions is complex and requires an&#x000a0;interprofessional team that includes oncology, pathology, radiology, and surgery clinicians, including medical assistants and technicians. Only through collaboration of the entire healthcare team can clinicians determine the optimal care plan for each patient, administer the necessary therapies, and monitor treatment response.<xref ref-type="bibr" rid="article-28510.r17">[17]</xref></p>
      </sec>
      <sec id="article-28510.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28510&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28510">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/rhabdomyosarcoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28510">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28510/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28510">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28510.s20">
        <title>References</title>
        <ref id="article-28510.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amer</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Congiusta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dobitsch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bozzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siracuse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aytekin</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Ghert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beebe</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, Incidence, and Survival of Rhabdomyosarcoma Subtypes: SEER and ICES Database Analysis.</article-title>
            <source>J Orthop Res</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>2226</fpage>
            <page-range>2226-2230</page-range>
            <pub-id pub-id-type="pmid">31161653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sisoudiya</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Martin-Giacalone</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Khayat</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Dugan-Perez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marquez-Do</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Scheurer</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Muzny</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boerwinkle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Barkauskas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Schiffman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Skapek</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Plon</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Sabo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lupo</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Germline Cancer Predisposition Variants in&#x02002;Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>113</volume>
            <issue>7</issue>
            <fpage>875</fpage>
            <page-range>875-883</page-range>
            <pub-id pub-id-type="pmid">33372952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bisogno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2020</year>
            <month>May</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>e28174</fpage>
            <pub-id pub-id-type="pmid">31994316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skapek</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Lupo</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shipley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyosarcoma.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2019</year>
            <month>Jan</month>
            <day>07</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">30617281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dorado Garcia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Scheer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henssen</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Current and Future Treatment Strategies for Rhabdomyosarcoma.</article-title>
            <source>Front Oncol</source>
            <year>2019</year>
            <volume>9</volume>
            <fpage>1458</fpage>
            <pub-id pub-id-type="pmid">31921698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Edmonson</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hedges</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yergeau</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Vadodaria</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hines-Dowell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nuccio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shurtleff</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rusch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Becksfort</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mardis</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Gajjar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ellison</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Pappo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Downing</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Germline Mutations in Predisposition Genes in Pediatric Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Dec</month>
            <day>10</day>
            <volume>373</volume>
            <issue>24</issue>
            <fpage>2336</fpage>
            <page-range>2336-2346</page-range>
            <pub-id pub-id-type="pmid">26580448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arndt</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Risk stratification of rhabdomyosarcoma: a moving target.</article-title>
            <source>Am Soc Clin Oncol Educ Book</source>
            <year>2013</year>
            <fpage>415</fpage>
            <page-range>415-9</page-range>
            <pub-id pub-id-type="pmid">23714563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Noguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanimoto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Embryonal rhabdomyosarcoma arising from the uterine corpus in a postmenopausal female: a surgical case challenging the genuine diagnosis on a cytology specimen.</article-title>
            <source>Diagn Pathol</source>
            <year>2016</year>
            <month>Jan</month>
            <day>12</day>
            <volume>11</volume>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">26755204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sardinha</surname>
                <given-names>MGP</given-names>
              </name>
              <name>
                <surname>Ramajo</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Ponce</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Bittencourt</surname>
                <given-names>CMF</given-names>
              </name>
              <name>
                <surname>Caldano</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Mo&#x000e7;o</surname>
                <given-names>JMFL</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>PMDR</given-names>
              </name>
              <name>
                <surname>Malaguti</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>de Sousa</surname>
                <given-names>CTRG</given-names>
              </name>
              <name>
                <surname>Nogueira</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Uterine cavity embryonal rhabdomyosarcoma.</article-title>
            <source>Autops Case Rep</source>
            <year>2019</year>
            <season>Jul-Sep</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>e2019104</fpage>
            <pub-id pub-id-type="pmid">31372362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agaram</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Evolving classification of rhabdomyosarcoma.</article-title>
            <source>Histopathology</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>98</fpage>
            <page-range>98-108</page-range>
            <pub-id pub-id-type="pmid">34958505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parham</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Classification of rhabdomyosarcoma and its molecular basis.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>387</fpage>
            <page-range>387-97</page-range>
            <pub-id pub-id-type="pmid">24113309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lav</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cherian</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Decoding the 'embryonic' nature of embryonal rhabdomyosarcoma.</article-title>
            <source>J Dev Orig Health Dis</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>163</fpage>
            <page-range>163-8</page-range>
            <pub-id pub-id-type="pmid">25740270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashi</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Hatley</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Galindo</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.</article-title>
            <source>Nat Rev Cancer</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>426</fpage>
            <page-range>426-39</page-range>
            <pub-id pub-id-type="pmid">26105539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeGeorge</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Hodges</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Bladder Cancer: Diagnosis and Treatment.</article-title>
            <source>Am Fam Physician</source>
            <year>2017</year>
            <month>Oct</month>
            <day>15</day>
            <volume>96</volume>
            <issue>8</issue>
            <fpage>507</fpage>
            <page-range>507-514</page-range>
            <pub-id pub-id-type="pmid">29094888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dagher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Helman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyosarcoma: an overview.</article-title>
            <source>Oncologist</source>
            <year>1999</year>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-44</page-range>
            <pub-id pub-id-type="pmid">10337369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Ewijk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schoot</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sparber-Sauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ter Horst</surname>
                <given-names>SAJ</given-names>
              </name>
              <name>
                <surname>Jehanno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Borgwardt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Keizer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Merks</surname>
                <given-names>JHM</given-names>
              </name>
              <name>
                <surname>de Luca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McHugh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>von Kalle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>van Rijn</surname>
                <given-names>RR</given-names>
              </name>
              <collab>Cooperative Weichteilsarkom Studiengruppe Imaging Group, the European Society of Paediatric Radiology Oncology Task Force and the European Paediatric Soft Tissue Sarcoma Study Group Imaging Committee</collab>
            </person-group>
            <article-title>European guideline for imaging in paediatric and adolescent rhabdomyosarcoma - joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology.</article-title>
            <source>Pediatr Radiol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>51</volume>
            <issue>10</issue>
            <fpage>1940</fpage>
            <page-range>1940-1951</page-range>
            <pub-id pub-id-type="pmid">34137936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphey</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kransdorf</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Staging and Classification of Primary Musculoskeletal Bone and Soft-Tissue Tumors According to the 2020 WHO Update, From the <italic>AJR</italic> Special Series on Cancer Staging.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>217</volume>
            <issue>5</issue>
            <fpage>1038</fpage>
            <page-range>1038-1052</page-range>
            <pub-id pub-id-type="pmid">33852362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Vries</surname>
                <given-names>ISA</given-names>
              </name>
              <name>
                <surname>van Ewijk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Adriaansen</surname>
                <given-names>LME</given-names>
              </name>
              <name>
                <surname>Bohte</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Braat</surname>
                <given-names>AJAT</given-names>
              </name>
              <name>
                <surname>Fajardo</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hiemcke-Jiwa</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hol</surname>
                <given-names>MLF</given-names>
              </name>
              <name>
                <surname>Ter Horst</surname>
                <given-names>SAJ</given-names>
              </name>
              <name>
                <surname>de Keizer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Knops</surname>
                <given-names>RRG</given-names>
              </name>
              <name>
                <surname>Meister</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Schoot</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Smeele</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>van Scheltinga</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Vaarwerk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Merks</surname>
                <given-names>JHM</given-names>
              </name>
              <name>
                <surname>van Rijn</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Imaging in rhabdomyosarcoma: a patient journey.</article-title>
            <source>Pediatr Radiol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>788</fpage>
            <page-range>788-812</page-range>
            <pub-id pub-id-type="pmid">36843091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fetzko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frances Wedekind</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Setty</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Schraw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lupo</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Guillerman</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Butala</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Walterhouse</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Okcu</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma?</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2022</year>
            <month>Aug</month>
            <day>01</day>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>305</fpage>
            <page-range>305-312</page-range>
            <pub-id pub-id-type="pmid">35137727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yechieli</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mandeville</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Hiniker</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bernier-Chastagner</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>McGovern</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scarzello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wolden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Breneman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fajardo</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyosarcoma.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2021</year>
            <month>May</month>
            <volume>68 Suppl 2</volume>
            <fpage>e28254</fpage>
            <pub-id pub-id-type="pmid">33818882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Beltangady</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gehan</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Crist</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Heyn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Intergroup Rhabdomyosarcoma Study-I. A final report.</article-title>
            <source>Cancer</source>
            <year>1988</year>
            <month>Jan</month>
            <day>15</day>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-20</page-range>
            <pub-id pub-id-type="pmid">3275486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crane</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Qumseya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>CAS</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Linardic</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Rodeberg</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rudzinski</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Shulkin</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Walterhouse</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Venkatramani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>69</volume>
            <issue>6</issue>
            <fpage>e29644</fpage>
            <pub-id pub-id-type="pmid">35253352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casey</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Mandeville</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ter Horst</surname>
                <given-names>SAJ</given-names>
              </name>
              <name>
                <surname>Sheyn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Timmermann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wolden</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Local control of parameningeal rhabdomyosarcoma: An expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT).</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>e29751</fpage>
            <pub-id pub-id-type="pmid">35484997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elsebaie</surname>
                <given-names>MAT</given-names>
              </name>
              <name>
                <surname>Amgad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elkashash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elgebaly</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ashal</surname>
                <given-names>GGEL</given-names>
              </name>
              <name>
                <surname>Shash</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Elsayed</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients.</article-title>
            <source>Sci Rep</source>
            <year>2018</year>
            <month>Jun</month>
            <day>19</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>9337</fpage>
            <pub-id pub-id-type="pmid">29921891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment for extremity rhabdomyosarcoma: longitudinal national questionnaire survey in Japan.</article-title>
            <source>Jpn J Clin Oncol</source>
            <year>2022</year>
            <month>Apr</month>
            <day>06</day>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>362</fpage>
            <page-range>362-369</page-range>
            <pub-id pub-id-type="pmid">34963137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Seitz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Routh</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Koscielniak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bisogno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodeberg</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>e28938</fpage>
            <pub-id pub-id-type="pmid">33522706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fernandez-Pineda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Spunt</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Parida</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krasin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Davidoff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>BN</given-names>
              </name>
            </person-group>
            <article-title>Vaginal tumors in childhood: the experience of St. Jude Children's Research Hospital.</article-title>
            <source>J Pediatr Surg</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>11</issue>
            <fpage>2071</fpage>
            <page-range>2071-5</page-range>
            <pub-id pub-id-type="pmid">22075335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filipas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fisch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gutjahr</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hohenfellner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Th&#x000fc;roff</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery.</article-title>
            <source>BJU Int</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-9</page-range>
            <pub-id pub-id-type="pmid">14678383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellerkamp</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Warmann</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Eckert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Paulsen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Detailed functional results after bladder-preserving surgery and high-dose-rate brachytherapy in pediatric bladder/prostate rhabdomyosarcoma.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>149</volume>
            <issue>7</issue>
            <fpage>3161</fpage>
            <page-range>3161-3170</page-range>
            <pub-id pub-id-type="pmid">35879432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodeberg</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wharam</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lyden</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Stoner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wolden</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Paidas</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Spunt</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.</article-title>
            <source>Int J Cancer</source>
            <year>2015</year>
            <month>Jul</month>
            <day>01</day>
            <volume>137</volume>
            <issue>1</issue>
            <fpage>204</fpage>
            <page-range>204-11</page-range>
            <pub-id pub-id-type="pmid">25418440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lautz</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wolden</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Routh</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Granberg</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Binite</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rudzinski</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Venkatramani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodeberg</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.</article-title>
            <source>Cancer</source>
            <year>2021</year>
            <month>Jan</month>
            <day>15</day>
            <volume>127</volume>
            <issue>2</issue>
            <fpage>275</fpage>
            <page-range>275-283</page-range>
            <pub-id pub-id-type="pmid">33079399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miwa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuchiya</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma.</article-title>
            <source>Cancers (Basel)</source>
            <year>2020</year>
            <month>Jul</month>
            <day>02</day>
            <volume>12</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">32630642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>The impact of radiotherapy on clinical outcomes in parameningeal rhabdomyosarcoma.</article-title>
            <source>Radiat Oncol J</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>290</fpage>
            <page-range>290-296</page-range>
            <pub-id pub-id-type="pmid">27609110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogeboom</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Grosser</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>D'Angio</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Breslow</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Stature loss following treatment for Wilms tumor.</article-title>
            <source>Med Pediatr Oncol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-304</page-range>
            <pub-id pub-id-type="pmid">11452938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulino</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Late effects of radiotherapy for pediatric extremity sarcomas.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2004</year>
            <month>Sep</month>
            <day>01</day>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>265</fpage>
            <page-range>265-74</page-range>
            <pub-id pub-id-type="pmid">15337565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hessels</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Langendijk</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gawryszuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heersters</surname>
                <given-names>MAAM</given-names>
              </name>
              <name>
                <surname>van der Salm</surname>
                <given-names>NLM</given-names>
              </name>
              <name>
                <surname>Tissing</surname>
                <given-names>WJE</given-names>
              </name>
              <name>
                <surname>van der Weide</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Maduro</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Review - Late toxicity of abdominal and pelvic radiotherapy for childhood cancer.</article-title>
            <source>Radiother Oncol</source>
            <year>2022</year>
            <month>May</month>
            <volume>170</volume>
            <fpage>27</fpage>
            <page-range>27-36</page-range>
            <pub-id pub-id-type="pmid">35257849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lockney</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Wexler</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Sklar</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wolden</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Late Toxicities of Intensity-Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>63</volume>
            <issue>9</issue>
            <fpage>1608</fpage>
            <page-range>1608-14</page-range>
            <pub-id pub-id-type="pmid">27195454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arndt</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Stoner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Rodeberg</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hayes-Jordan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Paidas</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Parham</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Teot</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Wharam</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Breneman</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Nov</month>
            <day>01</day>
            <volume>27</volume>
            <issue>31</issue>
            <fpage>5182</fpage>
            <page-range>5182-8</page-range>
            <pub-id pub-id-type="pmid">19770373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pappo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Crist</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Wharam</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Breitfeld</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Raney</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Womer</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Parham</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Qualman</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Grier</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group.</article-title>
            <source>J Clin Oncol</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>3487</fpage>
            <page-range>3487-93</page-range>
            <pub-id pub-id-type="pmid">10550146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzoleni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bisogno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garaventa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cecchetto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Donfrancesco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Casula</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>M</given-names>
              </name>
              <collab>Associazione Italiana di Ematologia e Oncologia Pediatrica Soft Tissue Sarcoma Committee</collab>
            </person-group>
            <article-title>Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma.</article-title>
            <source>Cancer</source>
            <year>2005</year>
            <month>Jul</month>
            <day>01</day>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <page-range>183-90</page-range>
            <pub-id pub-id-type="pmid">15895378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Inskip</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Fraumeni</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>The risk of developing second cancers among survivors of childhood soft tissue sarcoma.</article-title>
            <source>Cancer</source>
            <year>2005</year>
            <month>Jun</month>
            <day>01</day>
            <volume>103</volume>
            <issue>11</issue>
            <fpage>2391</fpage>
            <page-range>2391-6</page-range>
            <pub-id pub-id-type="pmid">15852362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heyn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ensign</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ruymann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vietti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report.</article-title>
            <source>Med Pediatr Oncol</source>
            <year>1994</year>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-106</page-range>
            <pub-id pub-id-type="pmid">8202048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korkmaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Topal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.</article-title>
            <source>Cell Biol Toxicol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-12</page-range>
            <pub-id pub-id-type="pmid">17225077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Sandlund</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Miser</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Arasi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Linehan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Magrath</surname>
                <given-names>IT</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.</article-title>
            <source>J Clin Oncol</source>
            <year>1987</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>799</fpage>
            <page-range>799-803</page-range>
            <pub-id pub-id-type="pmid">3106585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pringle</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Klingemann</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Reece</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.</article-title>
            <source>J Clin Oncol</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>2016</fpage>
            <page-range>2016-20</page-range>
            <pub-id pub-id-type="pmid">1941060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Rance</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Long term effects of cyclophosphamide on testicular function.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1985</year>
            <month>Nov</month>
            <day>23</day>
            <volume>291</volume>
            <issue>6507</issue>
            <fpage>1457</fpage>
            <page-range>1457-60</page-range>
            <pub-id pub-id-type="pmid">3933709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kenney</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Laufer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Grier</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Diller</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood.</article-title>
            <source>Cancer</source>
            <year>2001</year>
            <month>Feb</month>
            <day>01</day>
            <volume>91</volume>
            <issue>3</issue>
            <fpage>613</fpage>
            <page-range>613-21</page-range>
            <pub-id pub-id-type="pmid">11169946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishizawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iwanaga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer.</article-title>
            <source>Cancer</source>
            <year>1977</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>1403</fpage>
            <page-range>1403-9</page-range>
            <pub-id pub-id-type="pmid">851940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van de Velde</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kaspers</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Abbink</surname>
                <given-names>FCH</given-names>
              </name>
              <name>
                <surname>Wilhelm</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ket</surname>
                <given-names>JCF</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Vincristine-induced peripheral neuropathy in children with cancer: A systematic review.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>114</volume>
            <fpage>114</fpage>
            <page-range>114-130</page-range>
            <pub-id pub-id-type="pmid">28477739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: An analysis of 464 cases from the SEER database.</article-title>
            <source>Pediatr Investig</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>242</fpage>
            <page-range>242-249</page-range>
            <pub-id pub-id-type="pmid">33376951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28510.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oberlin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lyden</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bisogno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>May</month>
            <day>10</day>
            <volume>26</volume>
            <issue>14</issue>
            <fpage>2384</fpage>
            <page-range>2384-9</page-range>
            <pub-id pub-id-type="pmid">18467730</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
